Inmune Bio originally focused on using a dominant-negative TNF protein (DN-TNF) for cancer immunotherapy, which failed to show efficacy. Now, they’ve pivoted to neurology—repurposing the same molecule (XPro1595) for Alzheimer’s. The science behind targeting neuroinflammation is still early, and their approach lacks robust clinical validation.
They're in Phase 2, but data is sparse, the trial is small, and biomarkers—not clinical outcomes—are the main readout. With limited cash (~$20M as of last filing) and a high burn rate, they’ll likely need to raise before any real catalyst hits. High risk of dilution, weak scientific precedent, and a recycled failed asset = recipe for another disappointment.
Conclusion: This Alzheimer’s pivot feels like a Hail Mary. Market’s giving them credit for a turnaround that probably won’t work again ❌
They're in Phase 2, but data is sparse, the trial is small, and biomarkers—not clinical outcomes—are the main readout. With limited cash (~$20M as of last filing) and a high burn rate, they’ll likely need to raise before any real catalyst hits. High risk of dilution, weak scientific precedent, and a recycled failed asset = recipe for another disappointment.
Conclusion: This Alzheimer’s pivot feels like a Hail Mary. Market’s giving them credit for a turnaround that probably won’t work again ❌
Dagangan aktif
Always happy to create generational wealth for my followers
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.